rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AIM
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      aim immunoTech CEO buys $5,215 in common stock
      Nov 13Investing.comAIM
      AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results
      Nov 13Yahoo FinanceAIM
      aim immunotech ceo equels buys $5,070 in company stock
      Nov 11Investing.comAIM
      AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
      Nov 10Yahoo FinanceAIM
      aim immunoTech CEO Equels buys $3,166 in company stock
      Nov 7Investing.comAIM
      AIM ImmunoTech Highlights Ampligen® Opportunity to Potentially Extend Benefits of RAS-Targeted Therapies in Pancreatic Cancer
      Nov 5Yahoo FinanceAIM
      aim immunoTech CEO Equels buys $5,068 in common stock
      Oct 27Investing.comAIM
      Aim ImmunoTech CEO Equels buys $5,093 of common stock
      Oct 23Investing.comAIM
      AIM ImmunoTech Highlights Recent Media Coverage of Ampligen’s® Broad-Spectrum Antiviral and Biodefense Potential

      OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen® (rintatolimod), the Company’s investigational dsRNA and highly selective TLR3 agonist immunomodulator. Healthcare Business Today: AIM ImmunoTech CEO Tom Equels on Why Broad-Spectrum Antiviral Preparedness Cannot Wait for the Next OutbreakMediTech Today: What AIM ImmunoTech’s New Long COVID Patent Protectio

      Oct 5Yahoo FinanceAIM
      AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

      Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC programOCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage focused on the Company’s development strategy for Ampligen® (rintatolimod) in metastatic pancreatic cancer, including the scientific rationale for targeting immune resis

      Oct 1Yahoo FinanceAIM
      AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

      Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestonesAcce...

      Sep 30Business InsiderAIM
      AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

      Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancerSurvival data highlighted in accompanying...

      Sep 22Business InsiderRVMDAIM
      Aim ImmunoTech CEO Equels buys $4,992 in stock
      Sep 18Investing.comAIM
      Aim ImmunoTech CEO & president buys $2,310 in company stock
      Sep 17Investing.comAIM
      Aim ImmunoTech CEO & President Thomas Equels buys $4,862 in stock
      Sep 16Investing.comAIM
      AIM ImmunoTech Reduces Debt via Equity Exchange Agreements

      Detailed price information for Aim Immunotech Inc (AIM-A) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailAIM
      AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

      Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing the Company’s scientific strategy and continued a

      Sep 9Yahoo FinanceAIM
      AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

      Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom Latest milestone further strengthens AIM’s expanding global Ampligen patent estate across multiple therapeutic opportunities Follows newly issued U.S. patent covering Ampligen in combination with pembrolizumab for the treatment of cancer OCALA, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today an

      Sep 2Yahoo FinanceAIM
      AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

      Patent covers synergistic use of Ampligen with pembrolizumab across cancer indications, including pancreatic, ovarian, colorectal, breast, lung and other cancers, reinforcing the potential breadth and long-term value of AIM’s oncology platformOCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent covering the use of the Company's drug Ampligen in combi

      Aug 31Yahoo FinanceAIM
      AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference

      Video webcast now available here OCALA, Fla., Aug. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, AIM Chief Executive Officer Thomas Equels presented the Company's investment thesis, highlighting why he believes now is a pivotal time for AIM. The presentation discusses the Company's progress advancing Ampligen® through the Phase 2 DURIPA

      Aug 27Yahoo FinanceAIM
      Analysts Are Bullish on Top Healthcare Stocks: AIM ImmunoTech (AIM), Niagen Bioscience (NAGE)

      Detailed price information for Aim Immunotech Inc (AIM-A) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailAIM

      This is the newest page. Registered accounts read further back.